The Business Times

LA hospital warns 179 patients possibly exposed to 'superbug'

Published Thu, Feb 19, 2015 · 11:52 PM
Share this article.

[LOS ANGELES] A large Los Angeles teaching hospital has told scores of patients they were possibly exposed to a drug-resistant bacterial "superbug" during endoscopy procedures that infected seven patients and may have contributed to two deaths.

The 179 patients who may have been infected by the carbapenem-resistant Enterobacteriaceae, or CRE, are being offered home testing kits that would be analyzed by the University of California, Los Angeles, hospital system, UCLA officials said.

The possible exposures occurred at the UCLA Ronald Reagan Medical Center between October and January during procedures in which a specialized endoscope is inserted down the throat to diagnose and treat pancreatic and bile duct diseases.

Hospitals across the United States have reported exposures from the same type of medical equipment in recent years, and the US Food and Drug Administration has said it was working with other government agencies and scope manufacturers to minimize risks to patients.

The UCLA hospital system said it had been sterilizing the scopes according to the manufacturer's standards, but was now using a more rigorous process. "The two scopes involved with the infection were immediately removed, and UCLA is now utilizing a decontamination process that goes above and beyond manufacturer and national standards," it said in the statement.

UCLA spokeswoman Roxanne Moster said both scopes in question, which the hospital started using in June 2014, had been permanently set aside and would be returned to the manufacturer.

The circumstances of the two deaths of patients known to have been infected at Ronald Reagan Medical Center were not disclosed, nor were the conditions of the five other patients also confirmed to have been infected there.

Officials at the medical center were due to address a news conference later on Thursday.

UCLA became aware of the outbreak late last month, the Los Angeles Times reported. Both the Los Angeles County Department of Health Services and the California Department of Public Health were notified as soon as the bacteria were detected, the UCLA statement said.

Superbug infections are difficult to treat because some of the bacteria have become resistant to antibiotics, and the US Centers for Disease Control and Prevention said the germs could contribute to death in up to 50 percent of infected patients.

The complex design of the endoscopes linked to the California outbreak, known as duodenoscopes, may hinder proper cleaning, the FDA warned on Thursday.

The FDA said it wanted to raise awareness among healthcare professionals that the design is associated with a risk of multidrug-resistant infections even when a manufacturer's cleaning instructions are followed correctly.

There are three major manufacturers of the scopes: Olympus Corp, Fujifilm, and Pentax. Their disinfection recommendations were approved by the FDA.

Some experts advocate the use of disposable, single-use instruments, rather than reusable ones that must be sterilized after every procedure.

In January, Virginia Mason Medical Center in Seattle said that a bacteria spread through contaminated endoscopes had infected 32 people in that facility over two years.

Eleven of the patients infected from 2012 to 2014 eventually died. Since they were critically ill before being infected, it was unclear if the bacteria played any role in their deaths, health officials said.

Contaminated endoscopes also infected dozens of patients in Pittsburgh in 2012 and Chicago in 2014, health officials said. No fatalities were directly linked to those infections. "Superbugs" have been linked to 23,000 deaths and 2 million illnesses every year in the United States, and up to US$20 billion in direct healthcare costs.


BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to

Consumer & Healthcare


Get the latest coverage and full access to all BT premium content.


Browse corporate subscription here